MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek® 2025

Core Insights - MetaVia Inc. announced the acceptance of two abstracts for poster presentations at ObesityWeek® 2025, focusing on DA-1726, a novel dual oxyntomodulin analog agonist targeting cardiometabolic diseases [1][3]. Company Overview - MetaVia Inc. is a clinical-stage biotechnology company dedicated to transforming cardiometabolic diseases, currently developing DA-1726 for obesity treatment and Vanoglipel (DA-1241) for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [4]. Product Details - DA-1726 is a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR), administered once weekly subcutaneously, aimed at weight loss through appetite reduction and increased energy expenditure [3]. - In pre-clinical studies, DA-1726 showed superior weight loss compared to semaglutide and cotadutide, while also preserving lean body mass and demonstrating improved lipid-lowering effects compared to survodutide [3]. - The Phase 1 multiple ascending dose trial indicated that the 32 mg dose of DA-1726 has best-in-class potential for weight loss, glucose control, and waist circumference reduction [3][4]. Upcoming Presentations - The poster presentations will take place on November 4, 2025, at Exhibit Hall A1, featuring topics on the safety, tolerability, and pharmacokinetics of DA-1726, as well as its potential as a therapy for obesity and related metabolic disorders [6].